- Home
- SBSI vs SLBT Comparison
SBSI vs SLBT Comparison
Compare SBSI & SLBT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | SBSI | SLBT |
|---|---|---|
| Founded | 1960 | N/A |
| Country | United States | Taiwan |
| Employees | N/A | N/A |
| Industry | Major Banks | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 950.3M | 942.1M |
| IPO Year | 1995 | 2025 |
Fundamental Metrics
Financial Performance| Metric | SBSI | SLBT |
|---|---|---|
| Price | $30.49 | $1.60 |
| Analyst Decision | Hold | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $34.33 | N/A |
| AVG Volume (30 Days) | 97.1K | ★ 108.5K |
| Earning Date | 10-23-2026 | N/A |
| Dividend Yield | ★ 4.92% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.68 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $4.73 | N/A |
| Revenue Next Year | $3.13 | N/A |
| P/E Ratio | $18.11 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $26.32 | $1.42 |
| 52 Week High | $36.20 | $6.25 |
Technical Indicators
Market Signals| Indicator | SBSI | SLBT |
|---|---|---|
| Relative Strength Index (RSI) | 28.25 | 35.86 |
| Support Level | $30.06 | N/A |
| Resistance Level | $33.52 | $3.36 |
| Average True Range (ATR) | 0.62 | 0.18 |
| MACD | -0.12 | 0.02 |
| Stochastic Oscillator | 1.86 | 32.89 |
Price Performance
Historical ComparisonAbout SBSI Southside Bancshares Inc.
Southside Bancshares Inc is a bank holding company. Through its subsidiary, it operates as a financial institution offering various financial services to individuals, businesses, municipal entities, and nonprofit organizations. These services include consumer and commercial loans, deposit accounts, wealth management and trust services, brokerage services, and safe deposit services. The company's primary market areas are East Texas, Southeast Texas, and the greater Dallas-Fort Worth, Austin, and Houston, Texas.
About SLBT SL Science Holding Limited Ordinary Shares
SL Science Holding Ltd is a biomedical company specialized in developing cellular and gene therapies advancing regenerative medicine and cancer treatment. It utilizes immune stem cells to target cancer and bovine-derived milk exosomes to regenerate damaged tissues, thus potentially offering expansive medical applications for its products. With proprietary technologies such as Armed-T and Gamma Delta T cells, as well as exosome applications in skincare and cancer recovery. It operates in three segments namely Exosome products, CD-19 Armed-T products, and GDT cell therapy products. It derives revenue from Exosome products segment.